FDA Inspection 1304796 — Zhimin (NMI) Shao
The FDA completed an inspection of Zhimin (NMI) Shao on Feb 6, 2026 in Shanghai. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Feb 6, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Shanghai (China)
Additional details
Clinical Investigator (CI)